Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

HALO

Halozyme Therapeutics Inc

Dec 13 • 04:00PM ET

48.00

Dollar change +0.17
Percentage change 0.36	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: VTI IJH IWM VB VXF XBI VBK IWO MDY IBB

Scroll to Statements

Index	RUT	P/E	15.88	EPS (ttm)	3.02	Insider Own	1.06%	Shs Outstand	127.18M	Perf Week	-0.83%
Market Cap	6.13B	Forward P/E	10.44	EPS next Y	4.60	Insider Trans	-16.42%	Shs Float	125.88M	Perf Month	-18.10%
Income	392.47M	PEG	0.55	EPS next Q	1.17	Inst Own	99.40%	Short Float	6.81%	Perf Quarter	-23.70%
Sales	947.36M	P/S	6.47	EPS this Y	42.87%	Inst Trans	2.54%	Short Ratio	5.20	Perf Half Y	-3.03%
Book/sh	3.56	P/B	13.49	EPS next Y	16.13%	ROA	19.57%	Short Interest	8.57M	Perf Year	14.01%
Cash/sh	5.22	P/C	9.20	EPS next 5Y	29.00%	ROE	111.83%	52W Range	33.15 - 65.53	Perf YTD	29.87%
Dividend Est.	-	P/FCF	15.61	EPS past 5Y	-	ROI	20.06%	52W High	-26.75%	Beta	1.24
Dividend TTM	-	Quick Ratio	9.15	Sales past 5Y	41.16%	Gross Margin	74.59%	52W Low	44.80%	ATR (14)	1.87
Dividend Ex-Date	-	Current Ratio	10.36	EPS Y/Y TTM	61.49%	Oper. Margin	50.35%	RSI (14)	43.22	Volatility	3.12% 4.35%
Employees	373	Debt/Eq	3.32	Sales Y/Y TTM	21.35%	Profit Margin	41.43%	Recom	1.90	Target Price	64.00
Option/Short	Yes / Yes	LT Debt/Eq	3.32	EPS Q/Q	72.51%	Payout	0.00%	Rel Volume	0.56	Prev Close	47.83
Sales Surprise	15.03%	EPS Surprise	32.57%	Sales Q/Q	34.28%	Earnings	Oct 31 AMC	Avg Volume	1.65M	Price	48.00
SMA20	1.14%	SMA50	-7.05%	SMA200	-4.07%	Trades		Volume	928,064	Change	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48
Jan-21-21	Reiterated	The Benchmark Company	Buy	$46 → $59
Dec-17-20	Initiated	Berenberg	Buy	$50
Sep-14-20	Resumed	JP Morgan	Overweight	$28
Jul-01-20	Initiated	The Benchmark Company	Buy	$39

Show Previous Ratings

Dec-11-24 09:40AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Dec-09-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
09:40AM	Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? (Zacks)
Dec-05-24 12:45PM	Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now (Zacks)
09:40AM	Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Loading…
Nov-27-24 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Nov-22-24 12:12PM	Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook (Benzinga) +7.22%
12:00PM	Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why (Zacks)
09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
09:21AM	Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal (Investing.com)
08:35AM	Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions (PR Newswire)
05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive)
Nov-21-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Nov-19-24 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) (Zacks) +5.26%
09:40AM	Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now? (Zacks)
07:00AM	Loading…
Nov-18-24 07:00AM	Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec (PR Newswire) -6.75%
Nov-17-24 05:24PM	Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says (Bloomberg)
Nov-15-24 12:56PM	Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion (Benzinga) -15.40%
09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
05:11AM	Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid (Investing.com)
05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
03:36AM	Germanys Evotec Gets Takeover Interest From Halozyme (Bloomberg)
Nov-14-24 04:15PM	Halozyme Confirms Proposal to Combine with Evotec for 11.00 Per Share in an All-Cash Transaction (PR Newswire) -7.93%
Nov-04-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Nov-01-24 11:42AM	Halozyme Announces Record Earnings, Guidance (FX Empire) +13.01%
03:18AM	Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Oct-31-24 05:30PM	Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:10PM	Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
06:30AM	Loading…
Oct-24-24 06:30AM	HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE (PR Newswire)
Oct-23-24 04:30PM	Halozyme to Report Third Quarter 2024 Financial and Operating Results (PR Newswire)
Oct-17-24 01:02PM	State Street Corp's Strategic Acquisition in Halozyme Therapeutics Inc (GuruFocus.com)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Oct-14-24 09:35AM	Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options (Zacks)
Oct-07-24 12:10PM	Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again (Zacks) -9.01%
Oct-03-24 08:00AM	Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE (PR Newswire)
Sep-20-24 11:08AM	Global Cancer Rates Surge as Biotech Innovators Work on New Therapies (PR Newswire)
Sep-16-24 06:33AM	FDA approves Roches Ocrevus Zunovo with Halozyme Enhanze delivery tech (Pharmaceutical Technology)
Sep-13-24 01:30PM	Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis (PR Newswire)
Sep-12-24 08:00PM	Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With ENHANZE for Multiple Types of Cancer (PR Newswire)
Sep-10-24 06:59AM	Q1 2025 Avid Bioservices Inc Earnings Call (Thomson Reuters StreetEvents)
Sep-05-24 11:31AM	Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-24 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-28-24 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Aug-27-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Aug-23-24 03:03PM	Halozyme Earnings, Guidance Point to Bullish Future (FX Empire)
Aug-14-24 07:01PM	Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO) (GuruFocus.com)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Aug-07-24 04:11PM	How These Two Lesser-Known Biotech Names Obliterated Sales Expectations (Investor's Business Daily)
10:39AM	Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up (Zacks)
Aug-06-24 06:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
05:50PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:45PM	Halozyme Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:19PM	Halozyme And Ligand Two Leading Biotechs Smash Quarterly Forecasts (Investor's Business Daily)
04:01PM	HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Aug-05-24 09:16AM	Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Aug-04-24 01:33PM	3 Biotech Stocks on Track for 50% Returns (or More) by 2028 (InvestorPlace)
Jul-26-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Jul-23-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:30AM	Halozyme to Report Second Quarter 2024 Financial and Operating Results (PR Newswire)
Jul-18-24 07:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-16-24 05:11PM	Big Money Eyes Halozyme for Strong Growth (FX Empire)
Jul-15-24 09:04PM	3 Biotech Stocks to Buy Now: Q3 Edition (InvestorPlace)
Jul-09-24 12:45PM	Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think 'Yes' (Zacks)
Jul-08-24 12:42PM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Jul-05-24 06:20AM	3 Highly Rated Biotech Stocks for Your July Buy List (InvestorPlace)
Jul-03-24 08:00AM	How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin (Investor's Business Daily)
Jul-01-24 10:02AM	3 Breakout Biotech Stocks on Track to Double by 2032 (InvestorPlace)
Jun-25-24 01:15AM	Halozyme Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis (PR Newswire)
Jun-21-24 05:15PM	Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire)
Jun-17-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Jun-15-24 04:00PM	The 3 Best Healthcare Stocks to Buy in June 2024 (InvestorPlace)
Jun-13-24 07:00PM	Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO) (GuruFocus.com)
Jun-11-24 01:13PM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded by Piper Sandler (Insider Monkey)
09:50AM	Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
09:06AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Jun-07-24 01:52PM	Halozyme Therapeutics Scores RS Rating Jump To 91 (Investor's Business Daily)
08:59AM	Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13% (Zacks)
Jun-06-24 11:31AM	Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks) +12.68%
09:31AM	Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU (Zacks)
08:30AM	Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook (PR Newswire)
Jun-05-24 04:05PM	Halozyme Announces Issuance of New European Patent for ENHANZE Drug Delivery Platform (PR Newswire)
Jun-04-24 04:30PM	Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
May-31-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
May-21-24 07:15AM	Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE (PR Newswire)
May-20-24 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
May-16-24 02:55PM	Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating (Investor's Business Daily)
09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
May-10-24 12:39PM	Biotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled Breakout (Investor's Business Daily)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire)
06:15AM	The 3 Best Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-08-24 03:10PM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:34AM	Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates (Zacks)
08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
07:05AM	Q1 2024 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:52AM	Halozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-07-24 09:00PM	HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:00PM	Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:49PM	Halozyme Therapeutics Q1 2024 Earnings: Misses EPS Estimates but Shows Revenue Growth (GuruFocus.com)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Option Exercise	19.98	10,000	199,800	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Option Exercise	18.15	10,000	181,455	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Sale	53.75	10,000	537,469	173,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Sale	53.26	10,000	532,590	173,756	Oct 16 06:53 PM
MICHAEL LABARRE	Officer	Oct 16 '24	Proposed Sale	53.26	10,000	532,592		Oct 16 04:14 PM
MICHAEL LABARRE	Officer	Oct 15 '24	Proposed Sale	53.75	10,000	537,466		Oct 15 04:34 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Sale	54.00	10,000	539,961	676,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Sale	52.58	10,000	525,783	676,744	Oct 09 05:39 PM
HELEN TORLEY	Officer	Oct 09 '24	Proposed Sale	52.58	10,000	525,778		Oct 09 04:09 PM
HELEN TORLEY	Officer	Oct 08 '24	Proposed Sale	54.00	10,000	539,956		Oct 08 04:08 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Sale	58.21	10,000	582,100	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Sale	56.34	10,000	563,370	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Sale	56.10	10,000	560,970	676,744	Sep 26 06:06 PM
HELEN TORLEY	Officer	Sep 26 '24	Proposed Sale	56.10	10,000	560,970		Sep 26 04:05 PM
HELEN TORLEY	Officer	Sep 25 '24	Proposed Sale	56.34	10,000	563,368		Sep 25 04:00 PM
HELEN TORLEY	Officer	Sep 24 '24	Proposed Sale	58.21	10,000	582,101		Sep 24 04:05 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Sale	62.88	10,000	628,780	173,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Sale	62.03	10,000	620,316	173,756	Sep 18 06:49 PM
MICHAEL LABARRE	Officer	Sep 18 '24	Proposed Sale	62.03	10,000	620,311		Sep 18 04:01 PM
MICHAEL LABARRE	Officer	Sep 17 '24	Proposed Sale	62.88	10,000	628,777		Sep 17 04:03 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 12 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 12 '24	Sale	59.20	10,000	592,030	676,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '24	Sale	59.09	10,000	590,890	676,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '24	Sale	59.09	10,000	590,870	676,744	Sep 12 05:56 PM
HELEN TORLEY	Officer	Sep 12 '24	Proposed Sale	59.20	10,000	592,028		Sep 12 04:12 PM
HELEN TORLEY	Officer	Sep 11 '24	Proposed Sale	59.09	10,000	590,873		Sep 11 04:05 PM
HELEN TORLEY	Officer	Sep 10 '24	Proposed Sale	59.09	10,000	590,897		Sep 10 04:16 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 27 '24	Option Exercise	18.41	5,580	102,728	173,756	Aug 27 07:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Sale	61.75	10,000	617,470	168,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Sale	61.05	10,000	610,550	168,176	Aug 21 06:03 PM
MICHAEL LABARRE	Officer	Aug 21 '24	Proposed Sale	61.75	10,000	617,474		Aug 21 04:11 PM
MICHAEL LABARRE	Officer	Aug 20 '24	Proposed Sale	61.06	10,000	610,553		Aug 20 04:16 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Sale	57.95	10,000	579,490	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Sale	57.25	10,000	572,471	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Sale	56.25	10,000	562,490	676,744	Aug 15 04:59 PM
HELEN TORLEY	Officer	Aug 15 '24	Proposed Sale	57.95	10,000	579,488		Aug 15 04:31 PM
Posard Matthew L.	Director	Aug 14 '24	Sale	57.70	9,881	570,134	69,874	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 13 '24	Sale	56.19	10,000	561,930	79,755	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 12 '24	Sale	55.72	10,000	557,230	89,755	Aug 14 04:57 PM
HELEN TORLEY	Officer	Aug 14 '24	Proposed Sale	57.25	10,000	572,472		Aug 14 04:08 PM
HELEN TORLEY	Officer	Aug 13 '24	Proposed Sale	56.25	10,000	562,496		Aug 13 04:19 PM
Posard Matthew L.	affiliate	Aug 13 '24	Proposed Sale	54.15	30,000	1,624,500		Aug 07 04:41 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Option Exercise	15.19	10,000	151,854	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Option Exercise	8.11	10,000	81,100	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Sale	55.12	10,000	551,150	168,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Sale	54.89	10,000	548,873	168,176	Jul 24 05:48 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Option Exercise	22.50	5,000	112,500	19,488	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Sale	53.93	5,000	269,662	15,480	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Sale	52.04	10,000	520,400	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Sale	51.93	10,000	519,340	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	51.82	10,000	518,200	15,480	Jun 28 04:06 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Option Exercise	8.11	10,000	81,100	178,176	Jun 20 04:17 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Sale	49.43	10,000	494,260	168,176	Jun 20 04:17 PM
Posard Matthew L.	Director	Jun 12 '24	Sale	50.62	10,000	506,190	99,755	Jun 13 04:15 PM
Posard Matthew L.	Director	Jun 11 '24	Sale	50.01	10,000	500,110	109,755	Jun 13 04:15 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Sale	45.38	10,000	453,840	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Sale	45.16	10,000	451,640	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Sale	38.49	10,000	384,890	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Sale	38.35	10,000	383,500	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 26 '24	Option Exercise	11.20	11,618	130,160	168,176	Mar 26 07:38 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Option Exercise	12.07	10,000	120,700	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Option Exercise	10.66	10,000	106,638	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Sale	42.27	10,000	422,730	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Sale	41.64	10,000	416,370	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Option Exercise	8.11	7,471	60,590	164,029	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '24	Sale	39.95	10,000	399,460	159,087	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Sale	39.55	10,000	395,463	156,558	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,376	0	171,247	Feb 20 06:59 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Feb 16 '24	Option Exercise	0.00	4,796	0	14,257	Feb 20 06:55 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,422	0	18,344	Feb 20 06:53 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '24	Option Exercise	0.00	37,884	0	685,814	Feb 20 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '24	Option Exercise	0.00	3,386	0	160,529	Feb 16 05:47 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '24	Option Exercise	0.00	1,254	0	11,345	Feb 16 05:41 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '24	Option Exercise	0.00	13,092	0	651,096	Feb 16 05:39 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 10 '24	Option Exercise	0.00	8,133	0	160,044	Feb 13 04:18 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 10 '24	Option Exercise	0.00	2,502	0	11,568	Feb 13 04:15 PM
Torley Helen	PRESIDENT AND CEO	Feb 10 '24	Option Exercise	0.00	31,281	0	654,947	Feb 13 04:12 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HALO

Halozyme Therapeutics Inc

Upgrade your FINVIZ experience